Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 8/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303752 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2TSHRTP53EPHX2CCR3 | |
| SCHEMBL6312610 | 0.90 | FAAH (0.45) | CCR3FAAHTAS1R3TAS1R1MEN1 | |
| SCHEMBL6312616 | 0.90 | FAAH (0.45) | CCR3FAAHTAS1R3TAS1R1MEN1 | |
| SCHEMBL6312627 | 0.90 | FAAH (0.54) | SMN1; SMN2EPHX2CCR3FAAHTAS1R3 | |
| SCHEMBL6312632 | 0.90 | FAAH (0.54) | SMN1; SMN2EPHX2CCR3FAAHTAS1R3 | |
| SCHEMBL6311623 | 0.89 | CCR3 (0.54) | SMN1; SMN2EPHX2CCR3FAAHTAS1R3 | |
| SCHEMBL6311625 | 0.89 | CCR3 (0.54) | SMN1; SMN2EPHX2CCR3FAAHTAS1R3 | |
| SCHEMBL6304024 | 0.85 | CCR3 (0.55) | EPHX2CCR3FAAHTAS1R3TAS1R1 | |
| SCHEMBL6304021 | 0.85 | CCR3 (0.55) | EPHX2CCR3FAAHTAS1R3TAS1R1 | |
| SCHEMBL6311171 | 0.84 | RAB9A (0.52) | SMN1; SMN2CCR3FAAHMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | SMN1; SMN2 3011/4885TSHR 685/4885TP53 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.